• Dtsch. Med. Wochenschr. · Dec 2019

    [Current Standard of Care in Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Prevention, diagnostics, prognostication and therapy].

    • Michael Pogorzelski and Viktor Grünwald.
    • Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen.
    • Dtsch. Med. Wochenschr. 2019 Dec 1; 144 (24): 1691-1696.

    AbstractThe standard of care in squamous cell carcinoma of the head and neck (SCCHN) has recently undergone some major shifts in prevention, diagnostics, staging, prognostication and therapy.Prevention: Subtypes of the human papilloma virus (HPV) have been identified as causative agent for HPV-driven oropharyngeal carcinomas nearly two decades ago. Vaccination against HPV is now recommended for all girls and boys at the age of 9 to 14 years by the Standing Committee on Vaccination at the Robert Koch Institute (STIKO).Diagnostics: 18F-FDG PET/CT allows for a reduction of surgical procedures and is now reimbursed by the german health care system in certain indications. In N2/N3-disease after definitive chemoradiotherapy a FDG PET/CT is indicated to prevent neck dissection in PET negative patients. Moreover, a FDG PET CT is indicated in case of suspected recurrence of laryngeal carcinoma and as staging procedure in patients with cervical manifestation of CUP syndrome.Staging/prognostication: The favorable prognosis of HPV-driven oroparhyngeal carcinomas is now reflected by the 8th edition of the TNM classification. Therapeutic decisions should still be based on the established criteria of the 7th edition.Locally advanced disease: Treatment de-intensification strategies for HPV positive oropharyngeal carcinomas are currently evaluated. So far, the already published trials have reported a disadvantage for less intensive regimens. Therefore, de-intensification should not be practiced in current standard of care.Palliative systemic therapy: Checkpoint inhibitors nivolumab and pembrolizumab are the new standard of care after progression on platinum based therapies. In the Keynote-048 trial, treatment with either pembrolizumab alone (CPS > 1) or its combination with platin+ 5-flourouracil was superior to the current first line standard PFC.© Georg Thieme Verlag KG Stuttgart · New York.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.